| Released | Contributor | Author | Title | Pages | Price |
| 29-Nov-2009 | PriceTarget Research, Inc. |
N/A
| BSTCE has a current Overall Rating of C (Neutral). | 7 |
$25 |
| 24-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Industry Report for BIOTECHNOLOGY | 18 |
$49 |
| 23-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Detailed Valuation Report for BSTC | 13 |
$25 |
| 21-Nov-2009 | Standard & Poor's Quantitative Report |
N/A
| BioSpecifics Technologies | 5 |
$25 |
| 20-Nov-2009 | Pechala's Reports | Frantisek Pechala | BIOSPECIFICS TECHNOLOGIES CP (BSTC=US) 12-months forecast | 1 |
$15 |
| 20-Nov-2009 | Pechala's Reports | Lubomir Pechala | BIOSPECIFICS TECHNOLOGIES CP (BSTC=US) 2-weeks forecast | 1 |
$10 |
| 19-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Industry Value Graph: ACOR , AFFY , ANDS , BSTC , OMPI , TELK -- DRUGS | 3 |
$4 |
| 19-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Value Graph: BIOSPECIFICS TEC -- BSTC | 1 |
$4 |
| 17-Nov-2009 | EconomicInvestor |
N/A
| "The Economy Matters" Report for BSTC: the economy's impact on BSTC's price and risk, featuring the powerful EconomicInvestor Star Rating | 6 |
$15 |
| 12-Nov-2009 | Wright Reports |
N/A
| Wright Investors Service Comprehensive Report for BioSpecifics Technologies Corp. | 41 |
$65 |
0.29% Nasdaq 
Research Reports
